CRL Stock Analysis: Buy, Sell, or Hold?
CRL - Charles River Laboratories International, Inc.
$278.26
5.26 (1.93%)
â˛
5d:
-5.14%
30d:
-2.15%
90d:
+47.96%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When CRL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRL is fairly priced but lacks strong directional signals. At 9.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRL is fairly priced but lacks strong directional signals. At 9.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$315.19
Based on 8.1% avg growth
INTRINSIC VALUE TODAY
$195.71
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CRL is currently trading at $278.26, which is considered fair relative to its 30-day fair value range of $269.07 to $295.84. From a valuation perspective, the stock is trading at a premium (Forward PE: 21.9) compared to its historical average (16.9). At these levels, the market is pricing in 9.1% annual earnings growth.
Technical Outlook: Technically, CRL is in a strong uptrend. The price is currently testing key support at $272.06. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRL scores 19/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRL is in a strong uptrend. The price is currently testing key support at $272.06. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRL scores 19/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$269.07 -
$295.84
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
48.6%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (19/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($281.00)
- BULLISH: Expecting earnings turnaround to 9.1% growth with -2.7% revenue growth
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$269.07 -
$295.84
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$272.06
Resistance Level
$295.77
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.93
Wall Street Target
$281.00
(+1.0%)
Revenue Growth (YoY)
-2.7%
Earnings Growth (YoY)
-17.3%
Profit Margin
-6.0%
Valuation Premium vs History
+9.1% premium
PE vs Historical
21.9 vs 16.9
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.1%
(market-implied from PE analysis)
1-Year Target
$303.58
(+9%)
2-Year Target
$331.21
(+19%)
3-Year Target
$361.35
(+30%)
3-Yr Target (if PE normalizes)
(PE: 22â17)
PE COMPRESSION
$278.41
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 12.1%)
$391.83
(+41%)
Base:
(SPY PE: 20.2, Growth: 12.1%)
$360.31
(+30%)
Bear:
(PE: 16.9, Growth: 12.1%)
$301.89
(+9%)
Share & Embed Analysis
Last updated: September 12, 2026 2:34 AM ET
Data refreshes hourly during market hours. Next update: 3:34 AM
Data refreshes hourly during market hours. Next update: 3:34 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
NEUTRAL
Recent Transactions
Ro Khanna
BUY
2026-03-30
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$638 | 51 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$229 | 49 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 49 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$338 | 47 HOLD |
